Announcing the addition of a new cell-concentration approach to arthritis
As many are aware, I was an invited speaker to the Russian Orthopedic Society this past November. Although the purpose was for me to educate the attendees about advances in Cellular Orthopedics and Regenerative Medicine, I did become aware that a particular approach to arthritis under investigation in Europe in which I had great personal interest might soon be available for me in the United States. Three weeks ago, I underwent an autologous cellular and platelet concentration intervention into both of my knees so I could stay active and continue to pursue my personal fitness and recreational interests.
The Autologous Platelet Concentrate Fluid is designed to introduce anti-inflammatory cytokines and anabolic growth factors so as to decrease pain and promote cartilage well-being. Owing to my age, my circulating blood was used in a single injection in an attempt to stimulate my cartilage cell proliferation, block further cartilage destruction and slow my cartilage degradation. In a younger patient, I would chose Bone Marrow Concentrate as the means for blocking the inflammatory proteins Interleukin-1(IL-1) and Tissue Necrosis Factor-alpha (TNF-a). We now are able to offer this single injection intervention to those who might otherwise chose a Total Joint Replacement or who have not responded to previous regenerative interventions